The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Updates on the big 3 developments IB CAD, Gad Zero, IB Trax due soon. Each with the potential to transform the company.
Been a rough few months (for shareholders) but work has not ceased & with the grant and recent funding, developments will have been accelerated for a news rich 2022.
I would also expect news of contracts to pick up not only with the IB suite but if LSN and SC come in to play we will be of to the races. DYOR
In case you don't have access to auntminnie - 'The 510(k) clearance means qualified physicians can use the artificial intelligence (AI)-powered platform to manage imaging and other data across a network via web and customized user interfaces. That imaging and data can be processed by accessing and using integrated AI tools for imaging analysis and reporting.'
The negotiations are happening now so the start date is unknown. A website is not going to have privelaged information that shareholders do not regarding the start date. Given the life expectancy of the participants I would expect it to start as soon as the cause of delay is resolved.
https://www.plrinvest.com/
'Our firm specializes in growing companies.' 'Our expertise is in providing valuable counsel to smaller, growth-oriented, under-followed companies.' '...a truly unique capability to reach out to a targeted audience of industry participants, investors & financiers..'
The US PR machine is underway in good hands.
To come back to Brian re competition for Gad - I think IB are perfectly positioned to capitalise on a contrast free product. Firstly, 40% of MRI scans using an agent are neuro - IB already lead the way in Neuro imaging with their DSC approach which was acknowledged as the standard in DSC imaging in June 2020. The subsequent sales to Keck, Montgomery & LA County are validation of this (as well the the numerous clinical trials their tech is requested for as recognised by the US National Comprehensive Cancer Network & NCI).
There is only 1 other GAD free offering with many other research groups trying to develop a 0% but falling short. The results from the potential competitors have fallen short on the quality of their imaging & all still require some contrast agent (in some cases 10% - but this still means it has to be administered).
The huge competitive edge IB have are: 1. they will be contrast agent FREE 2. the quality of their imaging - so far no-one has been able to replicate the results of a contrast image to the standard of IB (this was the TB's 'wow' comment & results have been published) 3. IB has been patented (huge advantage).
Agreed - the SP currently has no relation to on-going operations.
In terms of buyout - I think the Gad free product and GaM trial will be watched closely & certainly attract interest from global players who could generate huge revenue's from a successful product on either score. Maybe products will be carved out for sale or someone may want to take IB lock stock.
I think news of GaM will be September & Gad FDA application could be anytime. I anticipate an update prior to trial start (broker appointment) but we will see how it plays out.
For now, it is a step at a time but the near future is looking extremely exciting.
IMO - IQAI are already showing signs they are readying themselves to becoming a much bigger player (in tandem with the position of their existing products and developments - IB Neuro, SC, IB Trax, GaM, Gad, IB CAD etc) with them choosing to not RNS all news & having a quieter presence on media platforms.
The next big indicator of this would be an appointment of a broker - which, to me, would show an ambition to attract larger investors, which implies an anticipation of mcap increase.
It is an easy hold for me - DYOR & each to their own strategy.
Ignoring all other existing products and developments, consider the potential global market for Gad free - IB are on the brink of applying for FDA clearance for their, now US patented, Gad (contrast) free imaging tech. The material cost of Gad is in the region of $1.3 billion per year in US alone without going into the costs of time and resource to administer the agents & associated harm to health that could bring potential litigation. If they crack this product it will transform the company.
??@IQAI_IB?? Software used to assess treatment response in a phase I clinical trial conducted at St. Jude's Hospital for Children pubmed.ncbi.nlm.nih.gov/33838625/, and grateful for our long-standing collaborative relationship to help combat high-grade brain tumors in younger patients.
The use of IB tech across many trials and institutions is a significant validation of their tech & will greatly assist its adoption as the standard choice.
I think 18p would seem cheap if they have success in Gad free or GaM. Those that have looked at the size and potential of the markets these pioneering developments can target will be here for the much larger rewards if/when this happens. I agree DYOR.
Sorry to hear that Drax. Maybe you should consider that people with GBM have an average of 14 months to live unless new treatments are offered. IQAI have stepped up to fund the GaM trials because they believe the treatment could offer a drastically improved outlook for these people. As said many times on here they will be using their tech to monitor the progress and could find out very early into the trial if the treatment is effective (10 days in animals). GaM could potentially be used on other tumours & offer significant hope to cancer sufferers - if successful this SP will seem very cheap indeed.
Also, existing products are being used in hospitals now (not in the future) with increasing market traction (LAC sale in 6 figures) - this could pick up on some of the newly releases products like LSN also now that marketing is underway.
Results of the recently patented Gad (contrast free) product they are working on are due near term & again if successful could be on the market in the near term & would significantly re-rate the SP. Remember this is a multi billion dollar market & due to the costs of contrast agents and the potential for law suits, an alternative would become immediately attractive to institutions.
These ground breaking products/treatments are not a million miles away - we know the rough timelines & IMO signs of success in either will wake people up here (if not Pi's then ii's).
510k application for JV development with Cortechs_ai for the neuro oncology platform - due
Gad Free update - due
GaM trial about to start.
There are many other updates we could see but this is a very exciting line up indeed...
I would be surprised if they are not seeking an appointment of a broker to attract institutional investors - maybe this happen around the start of the GaM trial!?
Unsure. The promising pathway act would effectively eliminate the longest phase (III) so i think it will be a lot shorter than they had originally anticipated. Also, the life expectancy of people with GBM is unfortunately only 14 months.
I think those early signs of how effective GaM is at ******ing the growth or reducing the tumour are what are going to be the most exciting results. As stated in the RNS 'Recent pre-clinical animal studies have shown that GaM can significantly reduce the size of tumours within 10 days of treatment' so it really might not be long before we have an idea of whether it will work.
"The discovery that GaM has anticancer activity against glioblastoma in an animal brain tumour model is extremely exciting; it opens the door for developing it as a drug for treatment of glioblastoma in patients", said Dr. Chitambar. "The anticancer mechanism of GaM applies to other solid tumours as well", Dr. Chitambar added.
If it appears to be successful for GBM sufferers then i think it is reasonable to assume from Dr Chitambar's statement above they would look at its application on other cancers. IMO it is a hugely exciting project.
IQAI just put a 6 figure sum in the bank with the sale of the IB to LAC.
IRO value as previously posted:
Tech companies like this are valued on 'potential' not revenue – potential is difficult to quantify and for markets to easily recognise, so you have to do enough research to have your own idea of what that equates to. By the time the big contracts come though, the market will have already caught on & this will be built into the SP.
Look at RENX 's half year report which showed a net loss of $14m with revenue of only $400,000 & yet their share price at the time was circa 990.00 which is a huge market cap for that revenue but valued on potential. They have since secured a government contract which shifted the SP to 1125.00 so largely had already been factored in. IMO IQAIs potential is currently overlooked, which can be illustrated by looking at the gulf in value between other tech companies in the sector like RENX.
I do agree that if we get news of contracts for LSN, SC, IB Neuro etc, it may be what shines a light on IQAI & we know an RNS can change things quickly here. None of us know when these share changing updates might land but we do know the products they are working on and rough time scales. It is up to you to decide if those products (including those recently released) have potential.
Gad free would be providing a cost/time/ saving for a multi billion dollar market (each year) & IB could be the first to offer this contrast free solution. If they are successful it will be massive for IQAI. I suspect it will gain interest from some of the global giants.